Effect of cadmium on cortisol production and 11beta-hydroxysteroid dehydrogenase 2 expression by cultured human choriocarcinoma cells (JEG-3)

Toxicology in Vitro : an International Journal Published in Association with BIBRA
Ana M RoncoMiguel N Llanos

Abstract

Cadmium is a toxicant with known carcinogenic and endocrine disruptor effects. We have previously reported that prenatal exposure to cadmium may induce low birth weight which is associated to increased foetal exposure to glucocorticoids; both signals constitute "hallmarks" of developmental programming. Since the effect of cadmium on the glucocorticoid system of placental carcinogenic cells is unknown, in the present work, we studied the effect of acute low dose of cadmium on cortisol production and 11beta-HSD2 expression and activity by cultured human choriocarcinoma cells (JEG-3). In addition, it was also evaluated whether those effects were related to the methylation index of the HSD11B2 gene, which can be regulated by epigenetic mechanisms. Cells were incubated with low cadmium dose (0.5 and 1 microM) for 24h and viability (MTT), cortisol production (EIA), 11beta-HSD2 expression (qRT-PCR) and activity (radioassay), and methylation index of the HSD11B2 gene were determined. Results show lower cortisol concentrations in the incubation media of exposed cells, which were associated to increased 11beta-HSD2 expression and activity and to a lower methylation index of the gene. These results suggest that cadmium-induced endocrine d...Continue Reading

References

Jul 1, 1995·The Journal of Clinical Endocrinology and Metabolism·Z KrozowskiR K Andrews
Apr 1, 1993·Current Opinion in Genetics & Development·P H Tate, A P Bird
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·C Q ZhaoM P Waalkes
Jun 1, 2000·Journal of Inorganic Biochemistry·M P Waalkes
Dec 19, 2001·The Journal of Pathology·Manel Esteller, James G Herman
Jan 25, 2002·Annual Review of Pharmacology and Toxicology·Jay I Goodman, Rebecca E Watson
Oct 29, 2003·Toxicology·Michael WaisbergDetmar Beyersmann
Jun 30, 2005·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Ana Maria RoncoMiguel Llanos
May 23, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Jonathan R Seckl, Megan C Holmes
Jun 22, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Susan E Ozanne, Miguel Constância
Sep 13, 2007·The Journal of Clinical Endocrinology and Metabolism·Eero KajantieJohan G Eriksson
Apr 15, 2009·Biochimica Et Biophysica Acta·Moshe Szyf
Aug 11, 2009·Current Opinion in Pediatrics·Andrea Baccarelli, Valentina Bollati
Apr 30, 2010·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Mariana BasergaRobert H Lane

❮ Previous
Next ❯

Citations

Jul 3, 2013·Nutrition Reviews·Pushpinder KaurDavid E Williams
Oct 17, 2013·European Journal of Human Genetics : EJHG·Yan ZhaoYunhui Zhang
Jan 23, 2016·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Marlon EspinozaNatalia Guiñazú
Jan 24, 2012·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Natalia GuiñazúGladis Magnarelli
Jul 28, 2016·Reproductive Toxicology·Joey St-PierreCathy Vaillancourt
May 12, 2015·Current Environmental Health Reports·Nadia VilahurKarin Broberg
Jan 18, 2020·Environmental Health Perspectives·Felicia Fei-Lei Chung, Zdenko Herceg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.